Literature DB >> 17084710

Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency.

Dinesh Gautam1, Oksana Gavrilova, Jongrye Jeon, Stephanie Pack, William Jou, Yinghong Cui, Jian H Li, Jürgen Wess.   

Abstract

Most animal models of obesity and hyperinsulinemia are associated with increased vagal cholinergic activity. The M3 muscarinic acetylcholine receptor subtype is widely expressed in the brain and peripheral tissues and plays a key role in mediating the physiological effects of vagal activation. Here, we tested the hypothesis that the absence of M3 receptors in mice might protect against various forms of experimentally or genetically induced obesity and obesity-associated metabolic deficits. In all cases, the lack of M3 receptors greatly ameliorated impairments in glucose homeostasis and insulin sensitivity but had less robust effects on overall adiposity. Under all experimental conditions tested, M3 receptor-deficient mice showed a significant elevation in basal and total energy expenditure, most likely due to enhanced central sympathetic outflow and increased rate of fatty-acid oxidation. These findings suggest that the M3 receptor may represent a potential pharmacologic target for the treatment of obesity and associated metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084710     DOI: 10.1016/j.cmet.2006.09.008

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  42 in total

1.  Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity.

Authors:  René L Jacobs; Yang Zhao; Debby P Y Koonen; Torunn Sletten; Brian Su; Susanne Lingrell; Guoqing Cao; David A Peake; Ming-Shang Kuo; Spencer D Proctor; Brian P Kennedy; Jason R B Dyck; Dennis E Vance
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.

Authors:  Burton M Wice; Songyan Wang; Dan L Crimmins; Kelly A Diggs-Andrews; Matthew C Althage; Eric L Ford; Hung Tran; Matthew Ohlendorf; Terry A Griest; Qiuling Wang; Simon J Fisher; Jack H Ladenson; Kenneth S Polonsky
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

3.  Cholinergic signaling inhibits oxalate transport by human intestinal T84 cells.

Authors:  Hatim A Hassan; Ming Cheng; Peter S Aronson
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-28       Impact factor: 4.249

Review 4.  Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

5.  Regulation of arcuate genes by developmental exposures to endocrine-disrupting compounds in female rats.

Authors:  Troy A Roepke; Jennifer A Yang; Ali Yasrebi; Kyle J Mamounis; Elif Oruc; Aparna Mahakali Zama; Mehmet Uzumcu
Journal:  Reprod Toxicol       Date:  2016-04-19       Impact factor: 3.143

Review 6.  Paracrine and autocrine interactions in the human islet: more than meets the eye.

Authors:  Alejandro Caicedo
Journal:  Semin Cell Dev Biol       Date:  2012-09-25       Impact factor: 7.727

7.  Gsα deficiency in adipose tissue improves glucose metabolism and insulin sensitivity without an effect on body weight.

Authors:  Yong-Qi Li; Yogendra B Shrestha; Min Chen; Tatyana Chanturiya; Oksana Gavrilova; Lee S Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

8.  Fat storage is partially dependent on vagal activity and insulin secretion of hypothalamic obese rat.

Authors:  Sandra Lucinei Balbo; Sabrina Grassiolli; Rosane Aparecida Ribeiro; Maria Lúcia Bonfleur; Clarice Gravena; Marcia do Nascimento Brito; Ana Eliza Andreazzi; Paulo Cezar de Freitas Mathias; Rosana Torrezan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

9.  The Gbeta5-RGS7 complex selectively inhibits muscarinic M3 receptor signaling via the interaction between the third intracellular loop of the receptor and the DEP domain of RGS7.

Authors:  Simone L Sandiford; Vladlen Z Slepak
Journal:  Biochemistry       Date:  2009-03-17       Impact factor: 3.162

10.  Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity.

Authors:  Tingqing Guo; William Jou; Tatyana Chanturiya; Jennifer Portas; Oksana Gavrilova; Alexandra C McPherron
Journal:  PLoS One       Date:  2009-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.